Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYAD NASDAQ:GDTC NASDAQ:IOBT NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsGDTCCytoMed Therapeutics$1.98+1.3%$1.95$1.20▼$4.05N/A-0.3882,290 shs16,274 shsIOBTIO Biotech$1.77-1.7%$1.79$0.66▼$2.79N/A0.411.24 million shs706,406 shsMNOVMediciNova$1.28$1.30$1.13▼$2.55N/A0.4326,409 shs10,724 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad0.00%0.00%0.00%0.00%0.00%GDTCCytoMed Therapeutics+1.97%-6.93%+0.32%-11.98%+26.00%IOBTIO Biotech0.00%+7.78%-0.55%+20.00%+100.42%MNOVMediciNova+1.59%-2.29%-5.19%-5.88%-32.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsGDTCCytoMed Therapeutics$1.98+1.3%$1.95$1.20▼$4.05N/A-0.3882,290 shs16,274 shsIOBTIO Biotech$1.77-1.7%$1.79$0.66▼$2.79N/A0.411.24 million shs706,406 shsMNOVMediciNova$1.28$1.30$1.13▼$2.55N/A0.4326,409 shs10,724 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad0.00%0.00%0.00%0.00%0.00%GDTCCytoMed Therapeutics+1.97%-6.93%+0.32%-11.98%+26.00%IOBTIO Biotech0.00%+7.78%-0.55%+20.00%+100.42%MNOVMediciNova+1.59%-2.29%-5.19%-5.88%-32.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad 0.00N/AN/AN/AGDTCCytoMed Therapeutics 3.00Buy$5.00153.16% UpsideIOBTIO Biotech 3.33Buy$8.00351.98% UpsideMNOVMediciNova 3.50Strong Buy$7.00446.88% UpsideCurrent Analyst Ratings BreakdownLatest CYAD, GDTC, IOBT, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/12/2025IOBTIO BiotechMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $4.007/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad$200KN/AN/AN/A$0.02 per shareN/AGDTCCytoMed Therapeutics$50KN/AN/AN/A$0.61 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AMNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AGDTCCytoMed Therapeutics-$1.84MN/A0.00∞N/AN/AN/AN/A9/30/2025 (Estimated)IOBTIO Biotech-$95.49M-$1.58N/AN/AN/AN/A-281.82%-169.29%11/11/2025 (Estimated)MNOVMediciNova-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)Latest CYAD, GDTC, IOBT, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IOBTIO Biotech-$0.35-$0.40-$0.05-$0.40N/AN/A8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyadN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad1.492.292.14GDTCCytoMed Therapeutics0.059.899.89IOBTIO Biotech4.221.961.96MNOVMediciNovaN/A13.2613.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyadN/AGDTCCytoMed Therapeutics0.04%IOBTIO Biotech54.76%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipCYADCelyad0.94%GDTCCytoMed TherapeuticsN/AIOBTIO Biotech2.30%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad95N/AN/ANot OptionableGDTCCytoMed TherapeuticsN/AN/AN/ANot OptionableIOBTIO Biotech30N/AN/ANot OptionableMNOVMediciNova10N/AN/AOptionableCYAD, GDTC, IOBT, and MNOV HeadlinesRecent News About These CompaniesMediciNova provides update on SEPA, COMBAT-ALS trial enrollmentSeptember 9 at 11:00 AM | msn.comMediciNova, Inc. Announces $30 Million Standby Equity Purchase Agreement and Reports Clinical Trial Enrollment SuccessSeptember 8 at 9:50 AM | quiverquant.comQMediciNova Provides Shareholder Update on Key DevelopmentsSeptember 8 at 9:00 AM | globenewswire.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | markets.businessinsider.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comMediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral CapitalAugust 29, 2025 | marketbeat.comMediciNova, Inc. Achieves Enrollment Target for COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 for ALS TreatmentAugust 26, 2025 | quiverquant.comQMediciNova Achieves Enrollment in COMBAT-ALS Clinical TrialAugust 26, 2025 | globenewswire.comMediciNova files to sell 25M shares of common stock for holdersAugust 22, 2025 | msn.comMediciNova (NASDAQ:MNOV) Posts Earnings Results, Meets ExpectationsAugust 18, 2025 | marketbeat.comMediciNova: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comMediciNova signs standby equity purchase agreement for up to $30MAugust 1, 2025 | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1, 2025 | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31, 2025 | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31, 2025 | globenewswire.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | globenewswire.comMediciNova, Inc. (MNOV) stock price, news, quote & history – Yahoo ...July 12, 2025 | au.finance.yahoo.comMediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comMediciNova price target lowered to $5 from $6 at B. RileyJune 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYAD, GDTC, IOBT, and MNOV Company DescriptionsCelyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.CytoMed Therapeutics NASDAQ:GDTC$1.98 +0.03 (+1.28%) Closing price 03:58 PM EasternExtended Trading$1.93 -0.05 (-2.28%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.IO Biotech NASDAQ:IOBT$1.77 -0.03 (-1.67%) Closing price 03:58 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.MediciNova NASDAQ:MNOV$1.28 0.00 (0.00%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
